Combination therapy for castration-resistant prostate cancer
Combination treatment has reshaped the care of metastatic castration-resistant prostate cancer (mCRPC), where disease progresses despite testosterone being held at castrate levels. Instead of relying on a single agent, clinicians may combine ongoing androgen deprivation therapy with medicines that block androgen signalling, chemotherapy, DNA-repair inhibitors or radioligand therapy. The correct sequence depends on tumour biology, previous treatment, fitness and access. Learn more about Les Festivals De Littérature Jeunesse Rencontres Et Ateliers à Travers L Europe.
For Australians, these decisions involve general practitioners, urologists, medical oncologists, radiation oncologists and nuclear medicine specialists. Major centres in Melbourne, Sydney and Brisbane offer advanced imaging and multidisciplinary services, while regional patients may rely on travel or teleoncology. A useful consultation should provide the full picture: expected benefit, likely harms, time burden, costs and what happens next.
Why combination treatment now matters
Castration resistance does not mean that hormones no longer matter. Prostate cancer can persist through androgen receptor amplification or mutations, renewed steroid production within the tumour, or changes in cell behaviour. Androgen deprivation therapy therefore remains the backbone in most mCRPC cases. Combination treatment is intended to block alternative survival routes or attack persistent tumour cells with a different class of medicine.
Biological selection is becoming more precise. The journal’s overview of emerging prostate biomarkers provides useful background on why prostate-specific antigen (PSA) alone cannot describe every prostate tumour, although early-detection biomarkers serve a different purpose from choosing treatment for established metastatic disease. In advanced disease, clinicians use genomic results, imaging, symptoms and laboratory trends to determine whether a combination is likely to add meaningful benefit.
These combinations are not interchangeable and should not be chosen merely because several drugs are available. Evidence differs by disease setting, molecular profile, prior exposure and fitness. A regimen that extends survival for one patient may add little for another while increasing fatigue, infection risk or treatment complexity. Sequencing is therefore a clinical decision, not a shopping list.
Building on the androgen receptor pathway
Most modern combinations start with continued androgen deprivation plus an androgen receptor pathway inhibitor. Abiraterone with prednisone reduces androgen production, while enzalutamide, apalutamide and darolutamide block androgen receptor signalling. In metastatic castration-resistant disease, an inhibitor can be paired with chemotherapy and, in eligible mutation-positive disease, with a PARP inhibitor. Product indications and subsidy in Australia should be checked for the exact medicine and setting.
Combining an androgen receptor inhibitor with a PARP inhibitor can be especially effective in metastatic disease driven by BRCA1 or BRCA2 alterations, with wider evidence in selected homologous recombination repair genes. Benefit varies by gene and regimen. After prior treatment, sequence matters: resistance may develop to the androgen receptor inhibitor while some tumour cells retain vulnerability to PARP inhibition.
Online descriptions can blur the distinction between approved combinations, treatment sequences and promotional claims. Search results may place unrelated commercial content, such as a live roulette betting page, beside medical information, making source labels especially important. Patients should use the journal, clinical guidelines, oncology services and official medicine information to check whether a proposed regimen is approved, evidence-based and available in Australia rather than relying on a headline or advertisement.
Chemotherapy, PARP inhibitors, and radioligands
Taxane chemotherapy remains a central option for medically fit patients with metastatic hormone-refractory prostate cancer. Continued androgen deprivation is maintained, and clinicians may retain an androgen receptor inhibitor in selected patients while docetaxel is delivered. Cabazitaxel is used after progression on a docetaxel-containing regimen. These treatments can control symptoms and extend survival, but infection, neuropathy, fatigue and nail changes require planning around work, travel and caregiving.
PARP inhibitors such as olaparib, rucaparib, talazoparib and niraparib exploit defects in tumour DNA repair. Niraparib with abiraterone is an established regimen for selected BRCA-mutated metastatic disease; other combinations may be used where authorised. Single-agent PARP treatment remains an option for some mutation-positive cancers when combination therapy is unsuitable. Adverse effects include anaemia, fatigue, thrombocytopenia and, for some agents, cardiovascular or drug-interaction risks.
PSMA-directed radioligand therapy is another route for metastatic disease that retains PSMA expression. It links a radioactive isotope to a molecule that binds PSMA, delivering radiation to prostate cancer cells and nearby metastases. Use in Australia depends on current regulatory approval, subsidy and local availability, while treatment selection requires PSMA imaging and specialist review. It may be used earlier or after other therapy, depending on eligibility, prior treatment and access.
Matching treatment to disease biology
Genomic testing can identify who may benefit most from PARP-directed treatment. Guidelines commonly recommend germline testing for metastatic prostate cancer, followed by tumour testing for alterations germline testing may miss. BRCA2, BRCA1 and ATM can influence treatment choices, while other high-risk genes may carry prognostic meaning even when no drug is available for that alteration. Results should be interpreted by a specialist and discussed with the patient and family.
Imaging helps determine disease burden and whether local treatment could still help. PSMA PET/CT is widely used in major Australian centres for staging and treatment planning, with CT, magnetic resonance imaging and bone scans providing additional information. Small-volume, low-symptom cancer and widespread bone-dominant disease may call for different approaches. Performance status, PSA trajectory, pain, fracture risk and speed of progression shape treatment intensity.
Urinary symptoms require their own assessment in men with advanced prostate cancer. Blood in the urine can arise from infection, stones, bladder lesions, catheter use or malignancy, and the cause may not be the prostate cancer itself. If haematuria is unexplained, a urologist may use cystoscopy for haematuria to inspect the bladder directly and direct further testing, with timing guided by symptoms and risk factors.
Managing toxicity and everyday treatment
Side effects can change the value of an otherwise effective regimen. Abiraterone may cause hypertension, liver enzyme changes and electrolyte disturbance; enzalutamide can worsen fatigue and increase falls; taxanes can suppress blood counts or cause neuropathy; PARP inhibitors may produce anaemia; and radioligand therapy can affect marrow, salivary glands and kidneys. Blood-pressure checks, medication reviews, blood monitoring and early management of fever or dehydration are often more effective than waiting for severe toxicity.
Access in Australia involves several checks. The Therapeutic Goods Administration assesses whether medicines are suitable for Australian use, but approval does not automatically mean Pharmaceutical Benefits Scheme subsidy. Medicare generally supports medical services rather than every outpatient cancer drug, and private insurance may leave gaps for hospital treatment or medicines. The treating team should confirm listings, out-of-pocket costs and whether a preferred agent must come from a particular hospital pharmacy.
Living with treatment adds practical burdens. People in regional and remote areas may need to travel for scans, reviews or radioligand administration, so community nursing, local blood tests and teleoncology can reduce disruption. Written plans should explain which symptoms need urgent review and how prescriptions will be supplied. Public information works best when tested with local communities; a village health case study from Indonesia offers a cross-cultural perspective on why context and language determine whether guidance can be used.
Sequencing care and shared decisions
No single sequence suits every man with metastatic castration-resistant disease. Decisions should follow disease characteristics, previous exposure and current evidence, including clinical trials where available. Multidisciplinary meetings in Melbourne, Brisbane and Sydney can be valuable, while regional networks can support local treatment with specialist input. Supportive care, palliative medicine and pain services can then be introduced early rather than only at the final stage.
Shared decisions work best when options are presented in plain English and uncertainty is stated directly. Patients and clinicians need to discuss whether treatment is intended to shrink tumours, relieve symptoms, prevent fractures or prolong life, because the trade-offs differ. Forums built around attentive listening, such as European literature festivals, offer a communication analogy: meaningful exchange depends on time, respect and hearing concerns that do not fit a clinical checklist.
Culturally safe care matters in a diverse country. Aboriginal and Torres Strait Islander patients should have access to appropriate Aboriginal health services and governance, and be supported by trusted clinicians, alongside qualified interpreters where needed. Plain phrases such as “what happens next?” and “what will it cost?” can clarify goals. In Australian outpatient conversations, getting the full picture means naming side effects, travel, time and realistic benefits without overselling any regimen.
If you are facing this diagnosis, make the next appointment count: ask your general practitioner or urologist about referral to a prostate cancer multidisciplinary team and whether genomic testing, PSMA imaging or a combination regimen is appropriate. Bring a medication list, scan reports, pathology results and a record of symptoms and side effects so each clinician can build one coherent plan.
Before starting treatment, request the expected benefit, common and serious harms, schedule, travel needs, out-of-pocket cost, and a clear plan for monitoring and what to do if the cancer progresses. Discuss clinical trial access and supportive care alongside drug treatment, then take the agreed plan home in writing.